drugset / Trial / NCT00323934

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00323934

Phase 1 Completed 42 enrolled Mirati Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.

Timeline

Start
2004-04
Primary completion
2007-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mocetinostat Small molecule Oral

Indications